IMMUNOREC

ImmunoRec is a spin-off company of the University of Crete aiming to enter phase-I clinical trial on cancer vaccine personalized therapy (patent ΟΒΙ 20190100297). The novel technology is stated by the National Medicinal Organization as Cancer immunotherapy with active substance autologous macrophages, pre-activated against autologous tumor antigens, absorbed on a silicon surface and is categorized as combined Advanced Therapy Medicinal Product. The company is to be built in an "Ex vivo Immunization Center" (EVIC), where patients will be receiving the personalized, self-tumor activated implant and monitored in collaboration with their oncologists. No side effects, No need to stop other treatments... ImmunoRec is the offspring of a 10-year laboratory work and collaboration of the Immunology Laboratory of the Department of Biology of the University of Crete with the Ultrafast Laser Micro- and Nano- processing Laboratory of the Institute of Electronic Structure and Laser of the Foundation..

Primary location: Crete Greece